Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 979
countries
28
conditions
2 106

115 trials match your criteria

Small cell lung cancer+2

Recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Small cell lung cancer

Recruiting

Phase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Small cell lung cancer extensive stage

Recruiting

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Atezolizumab

Hodgkin's disease

Recruiting

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin

Neuroendocrine carcinoma

Recruiting

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Small cell lung cancer

Recruiting

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Small cell lung cancer extensive stage

Recruiting

A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Small cell lung cancer

Recruiting

A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Allogenic stem cell transplantation

Recruiting

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan

B-cell lymphoma recurrent+1

Recruiting

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin

Hodgkin's disease

Recruiting

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.